Tomorrow belongs to the daring
We are Earlybird Venture Capital, optimistic risk-takers who roll up their sleeves
Our Founders
Erik Voorhees, CEO
Earlybird was among the very few VC firms that believed in the potential of digital assets before the hype.
Alexander Artopé, CEO
Earlybird and Christian Nagel have always been a strong partner, fully committed at any stage of our development. They were a great support to become the biggest pureplay for personal loans in Germany.
Daniel Dines, CEO
Earlybird was extremely active in helping us in the early days. They provided key customer introductions and helped me recruit our first new executives. Dan drove the creation of the investor syndicate and introduced me to our lead Series A investor.
Steve Atkinson, CEO
What sets the Earlybird team apart is their deep operating experience in medical devices, health and wellness. Management taps into their knowledge, insight and guidance — not just their capital. They are pragmatic, realistic and supportive and it is a genuine pleasure to have the Earlybird team at our side helping build the value of Atlantic Therapeutics.
About Us
Earlybird is a venture capital investor focused on European technology innovators.
Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support, as well as access to an international network and capital markets.
Earlybird Venture Capital has grown to three autonomous, dedicated and specialized teams, focusing on different geographies and sectors.
The Digital West Fund focuses primarily on early stage digital technology opportunities in GSA, Nordics, UK, Benelux, France and Southern Europe, while the Digital East Fund is focused on early stage ICT investment opportunities in Eastern Europe and Turkey, being the leading tech VC in this region. The Health Fund focuses on early and later stage opportunities in digital health, medical devices, diagnostics, enabling technologies and biopharma across Europe.
With over EUR 1 billion under management, seven IPOs and 24 trade sales, Earlybird is one of the most successful venture capital firms in Europe. Beyond delivering financial returns, we clearly see our own entrepreneurial responsibility for the environment as well as society and strive to make a positive contribution towards solving the global climate crisis. We are committed to running our own operations in a more eco-sustainable way and offset the residual carbon-footprint while expecting the same from our portfolio companies.
1
BILLION EUROS OF ASSETS UNDER MANAGEMENT
34
INVESTMENTS IN THE LAST 12 MONTHS
500
THOUSAND EUROS AS LOWEST INVESTMENT
47
PERMANENT EMPLOYEES
10
MILLION EUROS AS HIGHEST INVESTMENT
22
YEARS OF EXPERIENCE